Advert - Astellas Pharma Europe

• Date posted
  01 November 2017
• Sanction
  Advertisement,
• Case number/s
  AUTH/2958/5/17 - Voluntary admission by Astellas Europe

Astellas Pharma Europe voluntarily admitted that an electronic advertisement for Xtandi (enzalutamide), which incorrectly referred to an indication and a publication as new, had not been certified; additionally the company had not followed its withdrawal process and it was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry.
Clause 7.11 - Referring to an indication approved more than 12 months ago as new.
Clause 9.1 - Failing to maintain high standards.
Clause 14.1 - Failing to certify promotional material.